不可逆共价布鲁顿酪氨酸激酶抑制剂TAS5315对比安慰剂治疗甲氨蝶呤应答不足类风湿关节炎患者的随机双盲IIa期试验
这项IIa期双盲研究将91例甲氨蝶呤难治的日本类风湿关节炎患者随机分配至TAS5315 4 mg、2 mg或安慰剂每日一次治疗12周,主要终点第12周ACR20应答率在TAS5315联合组为78.9%、安慰剂组为60.0%(p=0.053),未达到主要终点;TAS5315似有一定出血风险,但所有RA疾病活动度指标的改善率均显示数值差异。
要点
- 第12周ACR20应答率TAS5315联合组78.9% vs 安慰剂组60.0%(p=0.053),主要终点未达到。
- TAS5315组常见不良事件为鼻咽炎(10.3%)、瘙痒(6.9%)和膀胱炎(5.2%)。
- 36周内9例患者发生出血事件,其中4例继续用药后恢复、2例中断用药后恢复、3例停用TAS5315后恢复。
核心结论
- 主要终点未达到。
- TAS5315似有一定出血风险,但所有RA疾病活动度指标的改善率与安慰剂相比均显示数值差异。
- 应考虑对TAS5315的风险获益进行进一步分析。
研究设计与样本
- IIa期双盲研究,A部分将甲氨蝶呤难治的日本类风湿关节炎患者随机分配至TAS5315 4 mg、2 mg或安慰剂每日一次治疗12周。
- B部分所有患者继续接受TAS5315治疗24周。
- A部分随机91例患者,84例进入B部分。
- 主要终点为第12周达到美国风湿病学会20%改善标准(ACR20)的患者比例。
主要发现
- 第12周ACR20应答率TAS5315联合组78.9% vs 安慰剂组60.0%(p=0.053)。
- 第12周ACR50应答率TAS5315联合组33.3% vs 安慰剂组13.3%(p=0.072)。
- 第12周ACR70应答率TAS5315联合组7.0% vs 安慰剂组0.0%(p=0.294)。
- 第12周TAS5315组达到低疾病活动度或缓解的患者多于安慰剂组。
- B部分期间临床和生物标志物改善得以维持。
局限性
- 主要终点未达到。
- TAS5315似有一定出血风险。
- 应考虑对TAS5315的风险获益进行进一步分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the efficacy and safety of TAS5315, an irreversible covalent Bruton's tyrosine kinase inhibitor, in Japanese patients with rheumatoid arthritis (RA) refractory to methotrexate. METHODS: In part A of this phase IIa double-blind study, patients were randomised to TAS5315 4 or 2 mg or placebo once daily for 12 weeks; in part B, all patients received TAS5315 for another 24 weeks. The proportion of patients meeting American College of Rheumatology criteria for 20% improvement (ACR20) at week 12 was assessed (primary endpoint). RESULTS: Ninety-one patients were randomised in part A, and 84 entered part B. At week 12, 78.9% of patients achieved ACR20 in the TAS5315 combined group vs 60.0% with placebo (p=0.053), 33.3% vs 13.3% achieved ACR50 (p=0.072) and 7.0% vs 0.0% achieved ACR70 (p=0.294), respectively. More patients receiving TAS5315 than placebo had low disease activity or remission at week 12. Clinical and biomarker improvements were maintained during part B. Adverse event (AE) incidence in TAS5315 was similar to placebo in part A; common AEs with TAS5315 were nasopharyngitis (10.3%), pruritus (6.9%) and cystitis (5.2%). Over 36 weeks, nine patients experienced bleeding events of whom four and two patients recovered with drug continuation and interruption, respectively. Three patients recovered after TAS5315 discontinuation. CONCLUSIONS: The primary endpoint was not achieved. TAS5315 appears to have some bleeding risks, but nevertheless demonstrated numerical differences, compared with placebo, in the improvement rates of all measures of RA disease activity. Future analysis of the risk-benefit of TAS5315 should be considered. TRIAL REGISTRATION NUMBERS: NCT03605251, JapicCTI-184020, jRCT2080223962.
引用
- Takeuchi T, Tanaka S, Murata M, et al. Irreversible covalent Bruton's tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial. Ann Rheum Dis. 2023. PMID: 37217273. doi:10.1136/ard-2022-223759
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。